Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Middle East & Africa Glucagon-like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 13-06-2019
Market Overview
For the last three decades, the Middle East & African countries have witnessed some critical social and economic transformations, which involve rapid economic growth and urbanization, along with reduced infant mortality and increased life expectancy.
Meanwhile, a few countries in the region have seen a decreased economy, due to political tension, along with other social factors, such as terrorism.
In the Middle East & Africa, approximately 35.5 million people live with diabetes. Middle Eastern countries have a high diabetes prevalence.
For instance, the percentages of type 2 diabetes in a few important countries are as follows: Saudi Arabia 24%, Kuwait 23%, Bahrain 22%, Qatar 20%, and UAE 19%.
It is estimated that only USD 17 billion was spent on diabetes, despite high prevalence in the region. Growth in the number of middle-class households, as well as increasing per capita income in these countries, will result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
Along with this, a few important factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.
The Middle East & Africa region suffers from a high burden of diabetes, and its adverse health and economic consequences. The disease should be viewed as a serious threat, not just from public health, but also from a development perspective. With risk factors, such as increasing obesity, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries in the region. It is one of the most common chronic diseases in Saudi Arabia, followed by Kuwait.
Scope of the Report
The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends –
Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes, among people of over 18 years, has accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three, by 2050 (according to the Center for Disease Control and Prevention).
The growing prevalence of diabetes is the primary driver for the global diabetes care drugs market. Additionally, raising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.
Saudi Arabia to Lead the GLP-1 Market
The GLP-1 market is expected to witness a high CAGR, of 13.4%, over the forecast period. Saudi Arabia is expected to hold the highest market share in the Middle East & Africa GLP-1 agonist market.
Victoza holds the highest market share in the region and the same trend is seen in Saudi Arabia. Trulicity is expected to have the highest growth during the forecast period (2019-2024)
The Saudi Arabian market is expected to see robust growth during the forecast period (2019-2024), due to the high number of R&D-related investments in the market. Some of these pipeline products are two of Sanofi’s GLP-1s, efpeglenatide and SAR425899, which are expected to launch in 2020 and 2021, respectively.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding their presence in all regions.
The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly, during the forecast period, due mainly to Trulicity and Ozempic.
Oral Semaglutide, which is in phase 3 of its clinical trials, is expected to launch by 2020. The product has shown better results than Januvia in studies.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 Middle East & Africa
5.2.1.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Egypt (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Iran (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.4 South Africa (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 Oman (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Egypt (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Iran (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Oman (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
North America Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 75 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 75 pages
- Published: 13-06-2019
Market Overview
The North America sodium-dependent glucose co-transporter 2 (SGLT2) market is expected to witness a tremendous growth during the forecast period (2019 – 2024), with a CAGR of 15.84%, mainly due to Jardiance and Farxiga/Forxiga, which launched globally in 2013 and 2014, respectively.
Jardiance is a once-daily oral medication that is used to control blood glucose levels in people with type 2 diabetes.
Jardiance has the highest growth among all the drugs in the SGLT-2 class of drugs, with a CAGR of about 21.4% during the forecast period (2019-2024). This is mainly because patients prefer this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT-2 class drugs.
Scope of the Report
The SGLT2 class of drugs includes Jardiance, Fraxiga, and Inovokana. The market growth for the drug Invonkana has been decreasing when compared to other SGLT2 class drugs, due to a large number of side effects, such as increasing weight and high cardiovascular risks for the patients. In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Suglat is a SGLT2 drug present only in Japan, with a market value of USD 93.29 million in 2017.
Key Market Trends –
Increasing Diabetes Population
As there is an exponential growth of the diabetes population year on year, especially type-2 diabetes, new innovative drugs are emerging in the market, for ease of access for the patients.
With this increase in diabetes population, the need and demand for diabetes drugs are expected to increase in North America.
The other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.
The North American SGLT2 market has a value for USD 4,205.99 million in 2019 and is expected to reach USD, witnessing a growth of 15.56% until the end of the forecast period. The United States accounts for 96.59% of the market, followed by Canada, which contributes around 3% of the SGLT-2 revenue in 2019.
At the brand level, Jardiance holds a significant market share at 43.48% in 2019. Jardiance also has a higher growth rate, at 21.31% which is considerably higher than the other two brands in this segment (Invokana and Farxiga/Forxiga).
The high CAGR can be attributed to the fact that Jardiance was introduced recently and is also used for other indications, such as diabetes-related cardiovascular diseases.
Overall, the SGLT2 market is expected to witness a considerable growth, owing to factors such as the rising diabetes population, constant R&D for the improvement of drug efficiency, and continuous updation of labels, among others.
Competitive Landscape
In June 2018, a new study on Jardiance reflected that the drug helps in reductions of kidney disease and cardiovascular risk.
In July 2017, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, to update the labels of Jardiance.
The labels will now include results from a trial that states that there is a relative risk reduction in hospitalization for heart failure, by 35%, and a relative risk reduction for new-onset or worsening of kidney disease, by 39%.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product (Market Value and Volume, 2012-2024)
5.1.1 Jardiance (Empagliflozin)
5.1.2 Farxiga/Forxiga (Dapagliflozin)
5.1.3 Invokana (Canagliflozin)
5.2 Geography
5.2.1 North America
5.2.1.1 US (Market Value and Volume, 2012-2024)
5.2.1.1.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.1.2 By Company (NovoNordisk, Sanofi Aventis, AstraZeneca, Bristol Myers Squibb, and Others)
5.2.1.2 Canada (Market Value and Volume, 2012-2024)
5.2.1.2.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.2.2 By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
5.2.1.3 Rest of North America (Market Value and Volume, 2012-2024)
5.2.1.3.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.3.2 By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
6 Competitive Landscape
6.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and Agreements
6.2 Market Share Analysis
7 MARKET INDICATORS
7.1 Type-1 Diabetes Population (2012-2024)
7.2 Type-2 Diabetes Population (2012-2024)
8 COMPETITIVE LANDSCAPE
8.1 COMPANY PROFILES
8.1.1 Janssen Pharmaceutical
8.1.2 Eli Lilly
8.1.3 AstraZeneca
8.1.4 Boehringer Ingelheim
8.1.5 Astellas
9 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product (Market Value and Volume, 2012-2024)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Invokana (Canagliflozin)
Geography
North America
US (Market Value and Volume, 2012-2024)
By Drug (Jardiance, Farxiga, and Invokana)
By Company (NovoNordisk, Sanofi Aventis, AstraZeneca, Bristol Myers Squibb, and Others)
Canada (Market Value and Volume, 2012-2024)
By Drug (Jardiance, Farxiga, and Invokana)
By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
Rest of North America (Market Value and Volume, 2012-2024)
By Drug (Jardiance, Farxiga, and Invokana)
By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The global DPP-4 inhibitors market was valued at USD 10.5 billion in 2018 and is expected to record a CAGR of 4% during 2019-2024. The North American DPP-4 drugs segment of the market studied accounted for the highest revenue, in 2018, and Latin America is expected to register the highest CAGR, of approximately 6%, during the forecast period.
Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period.
Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.
Scope of the Report
The DPP-4 inhibitors market is segmented by brands and covers the following brands: Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands. The report is segmented into five regions: North America, Asia-Pacific, Middle East & Africa, Latin America, and Europe.
Key Market Trends
The Tradjenta Market will Surpass Merck’s Januvia During the Forecast Period
The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county’s reimbursement authority, which concluded that it doesn’t provide any additional benefits, compared to the medicines already on the market.
North America Holds the Highest Market Share
The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.
Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.
Competitive Landscape
Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position until 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.1.1 Januvia (Sitagliptin)
5.1.1.2 Onglyza (Saxagliptin)
5.1.1.3 Tradjenta (Linagliptin)
5.1.1.4 Vipidia/Nesina (Alogliptin)
5.1.1.5 Galvus (Vildagliptin)
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012-2024)
5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.1.2 Canada (Value and Volume, 2012-2024)
5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012-2024)
5.2.2.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.2 Germany (Value and Volume, 2012-2024)
5.2.2.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.3 Italy (Value and Volume, 2012-2024)
5.2.2.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.4 Spain (Value and Volume, 2012-2024)
5.2.2.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
5.2.2.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.6 Russia (Value and Volume, 2012-2024)
5.2.2.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.2.2.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012-2024)
5.2.3.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3.2 Brazil (Value and Volume, 2012-2024)
5.2.3.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.2.3.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012-2024)
5.2.4.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.2 South Korea (Value and Volume, 2012-2024)
5.2.4.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.3 China (Value and Volume, 2012-2024)
5.2.4.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.4 India (Value and Volume, 2012-2024)
5.2.4.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.5 Australia (Value and Volume, 2012-2024)
5.2.4.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.6 Vietnam (Value and Volume, 2012-2024)
5.2.4.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.7 Malaysia (Value and Volume, 2012-2024)
5.2.4.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.8 Indonesia (Value and Volume, 2012-2024)
5.2.4.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.9 Philippines (Value and Volume, 2012-2024)
5.2.4.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.10 Thailand (Value and Volume, 2012-2024)
5.2.4.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.2.4.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.2.5.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.2 Iran (Value and Volume, 2012-2024)
5.2.5.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.3 Egypt (Value and Volume, 2012-2024)
5.2.5.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.4 Oman (Value and Volume, 2012-2024)
5.2.5.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.5 South Africa (Value and Volume, 2012-2024)
5.2.5.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
5.2.5.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Merck And Co.
7.1.2 AstraZeneca
7.1.3 Bristol Myers Squibb
7.1.4 Novartis
7.1.5 Takeda Pharmaceuticals
7.1.6 Eli Lilly
7.1.7 Boehringer Ingelheim
7.2 Company Share Analysis
7.2.1 Merck And Co.
7.2.2 AstraZeneca
7.2.3 Takeda Pharmaceuticals
7.2.4 Novartis
7.2.5 Eli Lilly & Boehringer Ingelheim
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Geography
North America
United States (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Canada (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of North America (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Europe
France (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Germany (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Italy (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Spain (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
United Kingdom (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Russia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Europe (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Latin America
Mexico (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Brazil (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Latin America (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Asia-Pacific
Japan (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Korea (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
China (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
India (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Australia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Vietnam (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Malaysia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Indonesia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Philippines (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Thailand (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Iran (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Egypt (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Oman (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Middle East & Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Cloud Collaboration Market – Growth, Trends, and Forecasts (2019 – 2024)
| Information & Communications Technology | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Information & Communications Technology
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The Cloud Collaboration market was valued at USD 26.11 billion in 2018 and is expected to register a CAGR of 13.43%, over the forecast period (2019-2024).
Employees across organizations use cloud-based collaboration platform to share and work together on projects at once. Cloud collaboration enables to achieve high productivity with access to real-time data. Cloud collaboration offers high agility to companies and enables easy data sharing among remote and virtual users. With changing business requirements, companies are now looking for services, which offer easy access and increased productivity thereby supporting the growing need for agile support.
With increasing automation trends along with the changing mobility, it has become increasingly important for industries to look for solutions that can offer services thereby reducing the overall infrastructure costs.
Moreover, businesses adopting mobile services and implementing new policies to increase the employee interaction and ease of use, has become important to provide accessibility to data across multiple end-point devices.
These services allow the client and employees to access files and data who are working on offsite locations, which makes operations much more accessible. It also lets users with BYOD (Bring your own device) to take full advantage of accessing the data over the cloud.
Scope of the Report
Cloud collaboration is a type of enterprise collaboration that allows employees to work together on documents and other data types, which are stored off-premises and outside of the company firewall. Employees use a cloud-based collaboration platform to share, edit and work together on projects. Cloud collaboration enables two or more people to work on a project at once.
Key Market Trends
Demand for Enterprise Social Collaboration is on the Rise
In recent years, enterprise social collaboration(ESC) solutions have been able to connect people around the world effectively. Social applications have been limited by technology and might work fine for one department but not for another. With the advent of the cloud, the integration of social collaboration solutions is easier than ever.
The demand for enterprise social collaboration is on the rise and with good reason. With the millennials becoming an increasingly larger part of the workforce, CIOs will be forced to face enterprise social collaboration (ESC) in the future. Intelligent CIOs-who are ahead of the trend have already embraced it, leading to staggering results.
When properly integrated, ESC solutions empower both employees and employer. It can instill the intimacy and fun of social media into work-related communications, and lead to accomplishing tasks in new and more efficient ways. Trusted partners and valued customers can also be integrated directly into the network to everyone’s mutual advantage.
Cloud Collaboration in North America is Driven by the Adoption of Cloud Computing
Cloud collaboration in the region is mainly driven by businesses that are adopting cloud computing to increase capacity and productivity. Companies in the region are moving beyond the public cloud and stepping into a new era of hybrid IT that combines public cloud, private cloud, and traditional IT. These organizations have implemented a hybrid cloud strategy as it is helping them to improve the way they run their business and deliver services to customers.
As per the RightScale’s State of the Cloud Report 2018, over 80% of the North American and European companies are using a complex deployment model in the cloud, i.e., 51% of the hybrid and 21% implementing a multi-cloud strategy, with an average of five cloud providers. This has further stimulated the cloud collaboration demand. With automation trends prominent in the region, it has become increasingly important for industries to look for solutions that can offer services to reduce infrastructure costs.
Also, the increased electronic device penetration has resulted in the high adoption of BYOD, which has forced companies to adopt cloud collaboration to address employee needs. Furthermore, the presence of prominent startups with an aggressive BYOD policy and freedom for employees has augmented the growth of the cloud collaboration market.
Competitive Landscape
The Cloud Collaboration Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with a prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. The companies operating in the market are also acquiring start-ups working on cloud collaboration technologies to strengthen their product capabilities. In Feb 2018, Cisco completed its acquisition of BroadSoft, which would accelerate Cisco’s cloud strategy and collaboration portfolio by adding the industry’s leading cloud calling and contact center solutions to Cisco’s leading calling, meetings, messaging, customer care, hardware endpoints, and services portfolio.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
2.1 Research Phases
2.2 Analysis Methodologies
3 EXECUTIVE SUMMARY
4 MARKET INSIGHTS
4.1 Market Overview
4.2 Industry Attractiveness Porters Five Force Analysis
4.2.1 Threat of New Entrants
4.2.2 Bargaining Power of Buyers/Consumers
4.2.3 Bargaining Power of Suppliers
4.2.4 Threat of Substitute Products
4.2.5 Intensity of Competitive Rivalry
4.3 Technology Snapshot
5 MARKET DYNAMICS
5.1 Introduction to Market Drivers and Restraints
5.2 Market Drivers
5.2.1 Increased Mobility and Changing Working Trends, Such as BYOD
5.2.2 Rising Need for Workforce Productivity and Enterprise Agility across Time Zones
5.3 Market Restraints
5.3.1 Data Security Concerns And Application Integration Complexities
6 MARKET SEGMENTATION
6.1 By Solution
6.1.1 Unified Communication and Collaboration
6.1.2 Enterprise Social Collaboration
6.1.3 Project and Team Management
6.1.4 Document Management System
6.1.5 Support Services
6.2 By Deployment Type
6.2.1 Public Cloud
6.2.2 Private Cloud
6.2.3 Hybrid Cloud
6.3 By End-user Industry
6.3.1 Telecommunication and ITES
6.3.2 Media and Entertainment
6.3.3 Education
6.3.4 Healthcare and Life Sciences
6.3.5 Banking and Financial System
6.3.6 Government and Public Sectors
6.3.7 Other End-user Industries
6.4 Geography
6.4.1 North America
6.4.2 Europe
6.4.3 Asia-Pacific
6.4.4 South America
6.4.5 Middle East and Africa
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Microsoft Corporation
7.1.2 Cisco Systems Inc
7.1.3 Oracle Corporation
7.1.4 HighQ Solutions
7.1.5 IBM Corporation
7.1.6 Box Inc.
7.1.7 Citrix Systems Inc.
7.1.8 Jive Software Inc
7.1.9 Mitel Networks Corp
7.1.10 Intralinks Holdings Inc.
7.1.11 Salesforce.com Inc.
7.1.12 Hyperoffice
7.1.13 Atlassian Corporation PLC
7.1.14 Adobe Systems
7.1.15 Zoho Corporation
8 INVESTMENT ANALYSIS
9 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Solution
Unified Communication and Collaboration
Enterprise Social Collaboration
Project and Team Management
Document Management System
Support Services
By Deployment Type
Public Cloud
Private Cloud
Hybrid Cloud
By End-user Industry
Telecommunication and ITES
Media and Entertainment
Education
Healthcare and Life Sciences
Banking and Financial System
Government and Public Sectors
Other End-user Industries
Geography
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Wireless Router Market – Growth, Trends, and Forecast (2019 – 2024)
| Information & Communications Technology | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 25-06-2019 |
- Information & Communications Technology
- Mordor Intelligence
- 100 pages
- Published: 25-06-2019
Market Overview
The Wireless Router Market is expected to register a CAGR of over 8.4% during the forecast period 2019 – 2024. Increasing consumer demand for web-enabled devices and growth in the IP traffic are the fundamental market drivers. Moreover, the increasing need for faster internet connectivity among consumers, which has deteriorated because of the rise in the number of devices being connected to the device, is spurring the demand for wireless routers with effective connectivity.
Internet traffic worldwide is growing rapidly, driven by more than 600 million new internet users, increasing Wi-Fi expansion, and demand for video services. With the rise in internet traffic and devices, the average fixed broadband speed, as well as average internet user will grow exponentially. Average fixed broadband speed is likely to grow from 5.1 Mbps in 2015 to 12.9 Mbps in 2020. This demands the use of wireless routers with enhanced bandwidths and internet speeds.
The growing trend of internet-enabled devices and rising need of internet connectivity are some of the major factors that are anticipated to impact the growth of the internet of things market positively, globally. Moreover, the importance of internet of things (IoT) is growing in industries and government organizations, owing to the rising need for remote monitoring systems and internet-enabled devices.
These devices and systems are enabled to operate efficiently and served better to their consumers. Likewise, consumers are creating a huge pressure to increase the consumption of internet of things on industries, by adopting smart devices to reduce the time for various processes of buying, shopping, etc.
In mobile broadband, there is a data-only SIM plan bundled with a 4G Wi-Fi modem. The modem handles the connection to the network the exact same way a mobile phone does. The performance is similar to that with mobile broadband plans on a laptop or a tablet. Moreover, it’s portable. One can take its dongle, Wi-Fi hotspot, mi-fi, or phone anywhere while traveling, moving home, streaming music in the car, or popping to a local café to do some work. On the other hand, fixed broadband is fixed and can only be used at home.
The Scope of the Report
A wireless router is a device that provides access to the Internet or computers, laptops, and tablets to a network. It allows users to share an Internet connection, files, or printers in a local area network (LAN). In addition, a wireless router connects a LAN to a wide area network (WAN) such as the Internet. A wireless router largely eliminates the need for awkward, unsightly wires, and allows multiple users to connect to a LAN and WAN.
Key Market Trends
802.11b is expected to register a Significant Growth
When compared to 802.11a standards, a major competitor to 802.11b at the time of deployment, there are several drawbacks identified in 802.11b routers. Firstly, it is slower and can cause high interference at the location of implementation as it operates in 2.4 GHz range, like most of the home appliances.
This was a tremendous competitive advantage to the deployment of 802.11a routers for commercial purposes, as they operate in the less crowded 5 GHz frequency band, making it less prone to interference. Secondly, unlike many modern standards, like 802.11g/n/ac, 802.11b is not interoperable with 802.11a, which adds to the list of factors that hindered the growth of 802.11b routers.
As of current market scenario, no wireless routers are being manufactured that adhere only to 802.11b standards. They mostly come in combinations with routers that support other standards as well, and are confined to usage in some research and industrial applications only. With further penetration of the internet into rural areas, especially in developing countries, and new amendments in the 802.11 standards, 802.11b is expected to go obsolete over the forecast period.
The United States is Expected to Hold Major Share
Globally, the United States is one of the most mature markets for the fixed broadband internet connections. By 2017, it was estimated that nearly 95.84 million people had fixed broadband connections. Furthermore, it was estimated that nearly 85.63% of the population has access to networks capable of speeds of 100 Mbps, depicting the need for high band of routers (as of 2017).
The presence of major technological giants, such as Cisco, D-Link, and TP-Link, coupled with the high adoption of technological trends in the country, aided the market for wireless routers. Moreover, the fixed broadband market is mature and is nearing saturation, with more than three out of every four US households anticipated to have a fixed broadband connection by the forecast period.
Consumer demand for fixed broadband access is expected to record sluggish growth. However, owing to the impact of mobile broadband services, it was estimated that more than 3.3 million fixed broadband subscriptions will be added, over the forecast period. Furthermore, increasing adoption of smart homes, with 30 million US households, is also favoring the conditions for wireless routers.
Competitive Landscape
The Wireless Router Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. The companies operating in the market are also acquiring start-ups working on Wireless Router technologies to strengthen their product capabilities. In March 2018, Taiwanese giant Foxconn, a manufacturer of iPhone for Apple, bought the accessory maker Belkin, as well as associated brands Wemo, Linksys, and Phyn, for USD 866 million in cash.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
Table of Contents
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Growth In Internet Traffic
4.3.2 Increasing Consumer Demand For Internet-enabled Devices
4.4 Market Restraints
4.4.1 Usage Of Mobile Broadband
4.5 Value Chain / Supply Chain Analysis
4.6 Industry Attractiveness Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Standard
5.1.1 802.11b
5.1.2 802.11g
5.1.3 802.11n
5.1.4 802.11ac
5.2 By Component
5.2.1 Product
5.2.2 Service
5.3 By End User
5.3.1 Residential
5.3.2 Commercial
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Russia
5.4.2.5 Spain
5.4.2.6 Others
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Rest of Asia-Pacific
5.4.4 Latin America
5.4.4.1 Brazil
5.4.4.2 Argentina
5.4.4.3 South Africa
5.4.4.4 Rest of South America
5.4.5 Middle East and Africa
5.4.5.1 UAE
5.4.5.2 Saudi Arabia
5.4.5.3 South Africa
5.4.5.4 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ASUSTeK Computer Inc.
6.1.2 Netgear Inc.
6.1.3 D-Link Corporation
6.1.4 Huawei Technologies Co. Limited
6.1.5 Xiaomi Inc
6.1.6 Belkin International Inc.
6.1.7 TP-Link Technologies Co. Limited
6.1.8 Mercury-PC
6.1.9 Buffalo Americas Inc.
6.1.10 Edimax Technology Co. Limited
6.1.11 Amped Wireless
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Standard
802.11b
802.11g
802.11n
802.11ac
By Component
Product
Service
By End User
Residential
Commercial
Geography
North America
US
Canada
Europe
Germany
UK
France
Russia
Spain
Others
Asia Pacific
China
Japan
India
Rest of Asia-Pacific
Latin America
Brazil
Argentina
South Africa
Rest of South America
Middle East and Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East and Africa
Li-Fi (Light Fidelity) Market – Analysis of Growth, Trends and Forecast (2019 – 2024)
| Investment Opportunities | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Investment Opportunities
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The Li-fi Market is expected to register a CAGR of over 70.54 % during the forecast period 2019 – 2024. Li-Fi is a disruptive technology that is poised to impact many industries. The technology can unlock the potential of IoT, drive Industry 4.0 applications and lead to the upcoming of light-as-a-service (LaaS) in the lighting industry. The CAGR of wireless traffic has been 60% during the last 10 years. This growth is expected to sustain for the next 10 to 15 years, which, in the current scenario is a reasonable assumption due to the advent of Internet-of-Things and machine type communication (MTC). It corresponds to a demand of 12,000 times the current bandwidth, assuming the same spectrum efficiency.
The governments are making efforts in the ICT sector, owing to the increasing need for energy management. Owing to government initiatives in the ICT sector, such as implementing smart city transformations, players are enforced to invest and innovate in Li-Fi. For instance, ICT is at the heart of the seven-year Dubai Plan 2021, which builds on investment in advanced technology by the emirate’s leadership, in combination with some private sector technology companies.
Moreover, the European Commission recognizes the enabling role that the ICT sector can play over the forecast period. For instance, rendering buildings more energy efficient or improving the functioning of the electricity grid and managing water. The concept of smart city encompasses optimizing the efficiency of city operations and services and connect citizens.
The limitations of the visible light provide Li-Fi with a security advantage over Wi-Fi. However, these limitations also create disadvantages. Physical barriers, such as walls and doors limit the operational scope of a Li-Fi-enabled LED lamp. Thus, the data transmitted by a Li-Fi product remains confined within a close spaced because light cannot penetrate opaque objects and has a shorter range. In establishments, such as a house or a building, enabled LED lamps must be strategically placed in rooms, halls, and other sections to expand the scope of the Li-Fi network. A single Wi-Fi router has wider and longer range than a Li-Fi router. These limitations of Li-Fi also do not make it ideal for use in public Wi-Fi networks.
Moreover, it cannot be used in outdoor environment like RF signal. This is because of interference caused by sunlight and other optical sources present nearby. Moreover it can be intercepted by unwanted people if used outdoors. Furthermore, Li-Fi is still in the emerging stage and very few have reached the commercialization stage.
Scope of the Report
Li-Fi is a wireless communication technology that uses the infrared and visible light spectrum for high-speed data communication. Li-Fi extends the concept of visible light communication (VLC) to achieve secure, bi-directional, high speed, and fully networked wireless communications. Li-Fi supports user mobility and multiuser access.
Key Market Trends
Indoor is Expected to register a Significant Growth
Smart buildings have begun to adapt to accommodate their residents, in order to improve resident comfort and user experience, by knowing the locations of each occupant and then provide location-based services, such as intelligent car parking, health monitoring, logistics, and shopping assistance. In addition to indoor shopping assistance, location-based service also plays a crucial role in the reduction of building energy cost. The basic idea of Li-Fi technology is to utilize the visible light from an LED light bulb to transmit high-speed data to a photodetector, which is connected to a smartphone or tablet.
Wi-Fi’s frequency spectrum is around 2.4GHz or 5GHz, while Li-Fi’s frequency spectrum is located in the visible light band. Considering the widespread use of LED bulbs inside buildings and large bandwidth of visible light, Li-Fi technology is much cheaper and more environment-friendly than Wi-Fi. Li-Fi technique has great potential in many popular applications, such as location-based services, mobile connectivity, smart lighting, and hazardous environments.The increasing growth in the use of LED lamps in buildings for lighting provides enormous opportunities for Li-Fi based applications. As Li-Fi combines the functions of high-speed wireless data communication and indoor lighting infrastructure, it is very cost-effective to be widely utilized in smart buildings.
The United States is Expected to Hold Major Share
The rapid advance of information technologies, such as wireless sensor network, internet of things, big data, and smartphones, have resulted in the development of smart buildings in the North American region. At the end of 2016, around 15 million households in the United States met the definition of smart home, which is expected to increase to more than 20 million households, thereby, offering several opportunities for Li-Fi in the country.
According to the US Green Building Council, building contributes a significant portion of energy consumption in the United States. It is reported that buildings account for 70% of electricity load and 39% of carbon oxide emissions. Given an occupant’s accurate indoor position, a building management system (BMS) is capable of offering highly-efficient heating, cooling, ventilation, and lighting service to the occupant.
Increasing applications of indoor location-based services embedded with light fixtures in retail shops and hotels in the North American region are also projected to be one of the factors driving the revenue growth in the region. Several companies, such as GE Lightings and ByteLight Inc. are deploying VLC installations in supermarkets, which, in turn, is aiding retailers to tie customers’ shopping history by tracking their location details.
Competitive Landscape
The Li-fi Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. The companies operating in the market are also acquiring start-ups working on Li-fi technologies to strengthen their product capabilities. In April 2018, pureLifi entered into partnership with Cisco in 5G RuralFirst project. This project is expected to support and inform the development of the UK’s 5G ecosystem, so that it is able to address the needs of communities and businesses in rural locations in ways that 4G, 3G, and 2G have not been able to do. pureLiFi is one among the project innovators working on 5G radio access technology and dynamic spectrum access.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Government Initiatives Pushing For Energy Efficiency
4.3.2 Rising Demand For High-speed Network
4.4 Market Restraints
4.4.1 Limited Range And Connectivity And Lack Of Awareness About The Technology
4.5 Value Chain / Supply Chain Analysis
4.6 Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Indoor
5.1.2 Outdoor
5.2 Geography
5.2.1 North America
5.2.2 Europe
5.2.3 Asia Pacific
5.2.4 Latin America
5.2.5 Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Panasonic Corporation
6.1.2 Koninklijke Philips NV
6.1.3 Renesas Electronics Corporation
6.1.4 Siemens AG
6.1.5 Velmenni
6.1.6 Zero1 Pte Ltd
6.1.7 PureLiFi
6.1.8 Oledcomm
6.1.9 LightBee Corp.
6.1.10 IDRO Co. Ltd
7 INVESTMENT ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Application
Indoor
Outdoor
Geography
North America
Europe
Asia Pacific
Latin America
Middle East and Africa